All In Biotech

Drug Trial Radar · NCT00081770

Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1

Last checked: Nov 20, 2026Latest source record: Apr 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,469 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,469

Actual

Start

Mar 2004

Primary completion

Nov 2007

Study completion Nov 2007

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 22, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.

Conditions

  • Hepatitis C, Chronic

Interventions

  • PegIntron (peginterferon alfa-2b; SCH 54031)Biological

    1.5 ug/kg/week subcutaneously (SC) for 48 weeks

  • PegIntron (peginterferon alfa-2b; SCH 54031)Biological

    1.0 ug/kg/week SC for 48 weeks

  • REBETOL (ribavirin; SCH 18908)Drug

    weight based dose 800-1400 mg/day orally (PO) for 48 weeks

  • PEGASYS (peginterferon alfa-2a)Biological

    180 ug/week SC administered for 48 weeks

  • COPEGUS (ribavirin)Drug

    1000-1200 mg/day PO for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained Virologic Response (SVR) RateTime frame: Assessed at the end of a 24-week post-treatment follow-up

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.